Chu Swee Yeok

Ms Chu joined EDB Investments Pte Ltd (EDBI) as its Chief Executive Officer in late 2008, bringing with her over 20 years of track record and extensive experience in equity investments of start-up to growth and late-stage ventures, strategic planning, business and technology development.. Prior to EDBI, Ms Chu was the CEO of BioOne Capital Pte Ltd since 2004. Under her leadership, BioOne became a globally recognised and reputable investment fund manager with a portfolio of over 50 therapeutics, medical technology and services companies worldwide and in Singapore. Previously Ms Chu held major stints at the Singapore Economic Development Board (SEDB) and the Agency for Science & Technology Research where she played a pioneering role in developing and implementing key industry and R&D strategies leading to the growth of the biomedical sector as a major pillar of Singapore's economy today. At SEDB she was instrumental in establishing several venture funds since 1990 and providing oversight to their management. Ms Chu was also responsible for many successful negotiations with global MNCs relating to their R&D, manufacturing and headquarters activities in Singapore. Besides the board of EDBI, Ms Chu also serves on the boards of Merlion Pharmaceuticals Pte Ltd, Singapore-Suzhou Township Development Pte Ltd, and Alexandra Health Endowment Fund.

Chu Swee Yeok is the CEO and President at EDBI, based in Asia. With a background in Financial Services, Chu Swee Yeok has a rich history of leadership and innovation. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.